Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.46B |
| 2 |
NVIDIA
NVDA
|
+$1.08B |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$609M |
| 4 |
Moderna
MRNA
|
+$599M |
| 5 |
UBS Group
UBS
|
+$478M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.11B |
| 2 |
Apple
AAPL
|
+$679M |
| 3 |
Palo Alto Networks
PANW
|
+$450M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$428M |
| 5 |
Microsoft
MSFT
|
+$361M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.97% |
| 2 | Financials | 8.75% |
| 3 | Healthcare | 7.15% |
| 4 | Consumer Discretionary | 6.46% |
| 5 | Communication Services | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMBM
3276
DELISTED
Cambium Networks
CMBM
| $394K | ﹤0.01% |
15,363
+1,197
| +8% | +$34.6K |
|
|
TRUE
3277
DELISTED
TrueCar
TRUE
| $394K | ﹤0.01% |
115,727
+76,756
| +197% | +$292K |
|
3278
iShares MSCI USA Quality Factor ETF
QUAL
$46.4B
| $393K | ﹤0.01% |
2,700
-297
| -10% | -$42K |
|
|
VRAY
3279
CALL
DELISTED
ViewRay, Inc.
VRAY
| $393K | ﹤0.01% |
+71,300
| New | +$434K |
|
3280
Vera Bradley
VRA
$97M
| $392K | ﹤0.01% |
45,983
+16,535
| +56% | +$159K |
|
|
TECX
3281
Tectonic Therapeutic
TECX
$529M
| $389K | ﹤0.01% |
8,426
+3,697
| +78% | +$212K |
|
3282
PUT
Chubb
CB
$135B
| $386K | ﹤0.01% |
+2,000
| New | +$376K |
|
3283
Kopin
KOPN
$652M
| $385K | ﹤0.01% |
94,199
+62,483
| +197% | +$317K |
|
|
TCS
3284
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $385K | ﹤0.01% |
2,573
+1,707
| +197% | +$288K |
|
3285
American Coastal Insurance
ACIC
$515M
| $384K | ﹤0.01% |
88,443
+13,624
| +18% | +$58.5K |
|
3286
ProShares Ultra Gold
UGL
$650M
| $384K | ﹤0.01% |
25,680
-10,960
| -30% | -$159K |
|
|
KALV
3287
DELISTED
KalVista Pharmaceuticals
KALV
| $383K | ﹤0.01% |
28,986
+18,582
| +179% | +$296K |
|
|
CLVS
3288
DELISTED
Clovis Oncology, Inc.
CLVS
| $383K | ﹤0.01% |
141,246
+91,907
| +186% | +$340K |
|
3289
Lifetime Brands
LCUT
$191M
| $382K | ﹤0.01% |
23,986
+10,205
| +74% | +$176K |
|
3290
Viking Therapeutics
VKTX
$3.7B
| $382K | ﹤0.01% |
83,032
+54,515
| +191% | +$306K |
|
3291
Q32 Bio
QTTB
$466M
| $380K | ﹤0.01% |
5,812
+2,977
| +105% | +$289K |
|
|
BBBY
3292
PUT
DELISTED
Bed Bath & Beyond Inc
BBBY
| $379K | ﹤0.01% |
26,000
| – | – |
|
3293
Autoliv
ALV
$9.02B
| $378K | ﹤0.01% |
3,653
-59,585
| -94% | -$5.85M |
|
3294
Assembly Biosciences
ASMB
$498M
| $378K | ﹤0.01% |
13,496
-4,252
| -24% | -$139K |
|
3295
Home Bancorp
HBCP
$561M
| $377K | ﹤0.01% |
9,090
+5,964
| +191% | +$245K |
|
3296
CALL
Synchrony
SYF
$24.7B
| $376K | ﹤0.01% |
8,100
| – | – |
|
|
CSLT
3297
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $376K | ﹤0.01% |
243,747
+99,988
| +70% | +$165K |
|
3298
InfuSystem Holdings
INFU
$184M
| $374K | ﹤0.01% |
21,981
+14,579
| +197% | +$231K |
|
3299
NWPX Infrastructure Inc
NWPX
$1.19B
| $374K | ﹤0.01% |
11,760
+7,804
| +197% | +$215K |
|
3300
Sprott Physical Silver Trust
PSLV
$12B
| $374K | ﹤0.01% |
46,656
-14,625
| -24% | -$119K |
|
Similar funds
Barclays's Q4 2021 Portfolio in Review
As of Q4 2021, Barclays held 5,008 positions worth $268B, up 21% from $222B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Barclays deployed $30.5B of net new capital in Q4 2021, opening 209 new positions and adding to 2,223 existing holdings. Its largest new stake was UBS Group: 27,173,428 shares worth $486M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.11B trimmed.
- Barclays's largest Q4 2021 buy was UBS Group: 27,173,428 shares worth $486M.
- Barclays added most to iShares 20+ Year Treasury Bond ETF in Q4 2021, an estimated $1.46B increase.
- Barclays's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.11B.
- Barclays fully exited Vanguard Total International Bond ETF in Q4 2021, selling an estimated $89.8M.
- Barclays's ten largest holdings make up 30% of its $268B portfolio in Q4 2021.
- Barclays opened 209 new positions and closed 867 in Q4 2021.
- Barclays's portfolio value rose 21% quarter-over-quarter to $268B.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.